Main Findings: BCL2 inhibitors like venetoclax have achieved high response rates (ORR >70%) in CLL and AML but face resistance <i>via</i> MCL1/BCL-XL upregulation. The gene discussed is BCL2L1; the disease is B-cell chronic lymphocytic leukemia.